ESTRELLA IMMUNOPHARMA, INC. Deferred Tax Assets, Operating Loss Carryforwards, State and Local
ESTRELLA IMMUNOPHARMA, INC. (ESLA) had Deferred Tax Assets, Operating Loss Carryforwards, State and Local of $6.50 million as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal · last filed 2026-03-18
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $6.50M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $6.50M.
- 2024-06-30: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $6.50M.
- 2023-06-30: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $6.50M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, State and Local |
|---|---|
| 2025-12-31 | $6.50M 10-K · filed 2026-03-18 |
| 2024-12-31 | $6.50M 10-K · filed 2026-03-18 |
| 2024-06-30 | $6.50M 10-KT · filed 2025-03-25 |
| 2023-06-30 | $6.50M 10-K · filed 2024-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |